Posts

Progress of Federal Taxotere Hair Loss Lawsuits

Taxotere Lawsuit News

Taxotere Lawsuit News: Federal Litigation to Convene Five Bellwether Trials Starting May 2019

The federal court overseeing thousands of Taxotere lawsuits filed over the chemotherapy drugs’ alleged potential to cause permanent hair loss will convene five bellwether trials beginning in May 2019.

According to an Order issued in the U.S. District Court, Eastern District of Louisiana, on June 13th, the first trial will be convened May 13th-24th. The case selected for trial will be chosen from a pool of lawsuits filed on behalf of 4 Louisiana residents:

Durden, Antoinette 2:16-cv-16635
Earnest, Barbara 2:16-cv-17144
Francis, Tanya 2:16-cv-17410
Tuyes, Lisa 2:16-cv-15473
The remaining trials will be convened on the following dates:

September 16-27, 2019
January 27-February 7, 2020
May 11-22, 2020
September 14-25, 2020
Taxotere Hair Loss Allegations
Taxotere (docetaxel) is a chemotherapy drug marketed by Sanofi-Aventis. It was initially approved by the U.S. Food & Drug Administration (FDA) in 1996 to treat breast cancer. However, its approved indications have since been expanded to include the treatment of head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer.

The first generic version of docetaxel was approved by the FDA in 2010.

Temporary hair loss is a common side effect of most chemotherapy agents. However, Taxotere hair loss plaintiffs allege that alopecia associated with docetaxel is far more likely to be permanent compared to equally effective alternative medications.

Among other things, their complaints note that the European medical community was informed of the potential for docetaxel-induced permanent hair loss in 2005, while the Canadian Taxotere label underwent a similar modification in 2012. However, mention of this potential side effect was not added to the U.S. label until 2015.

What are Bellwether Trials?

More than 8,700 Taxotere lawsuits are currently pending in the Eastern District of Louisiana, where all federally-filed hair loss claims involving the drug have been centralized in a multidistrict litigation to facilitate coordinated discovery and other pretrial proceedings.

The litigation’s bellwether trials are intended to serve as test cases, and their verdicts could provide insight into how other juries will decide similar Taxotere lawsuits.

While there is no guarantee, bellwether trial verdicts also sometimes help pave the way for a global settlement of all claims pending in a multidistrict litigation.

Taxotere Lawsuit News

Source

Hundreds Seek To Centralize NJ Taxotere Hair Loss Suits

Progress of Federal Taxotere Hair Loss Lawsuits

Taxotere Permanent Alopecia Lawsuits Move Forward with Issuance of New Pretrial Orders

Taxotere Permanent Alopecia Lawsuits Move Forward with Issuance of New Pretrial Orders

New Pretrial Orders have been filed by the federal court overseeing hundreds of product liability claims involving the chemotherapy drug Taxotere and its alleged potential to cause permanent alopecia.

Pretrial Order No. 49, filed in the U.S. District Court, Eastern District of Louisiana on July 6th, adopts a protocol for the production of electronically stored information (ESI).

The protocol addresses the scope of ESI discovery, search methodology, timing of discovery, format of production and other matters.

It also directs each of the parties to designate a liaison to coordinate all ESI requests and responses.

Pretrial Order No. 50 was also issued on July 6th and adopts a Protective Order that sets forth guidelines governing the disclosure of certain confidential information, including.

  • Information prohibited from disclosure by law
  • Information that reveals trade secrets
  • Research, technical, commercial or financial information that the party has maintained as confidential
  • Medical and protected health information (“PHI”) concerning any individual
  • Personal identifying information
  • Income tax returns (including attached schedules and forms), W-2 forms and 1099 forms
  • Personnel or employment records of a person who is not a party to the case

Taxotere Hair Loss Lawsuit

Taxotere Lawsuit Allegations

Court records indicate that more than 1,100 Taxotere lawsuits are currently undergoing coordinated pretrial proceedings in the Eastern District of Louisiana.

All federally-filed hair loss claims involving the cancer drug were transferred to Louisiana last October, after the U.S. Judicial Panel on Multidistrict Litigation determined that the growing docket would benefit from consolidation.

Taxotere was brought to market by Sanofi-Aventis in 1996, and was initially approved to treat breast cancer. Its approved indications have since been expanded to several other cancers. It wasn’t until December 2015, however, that the U.S. Taxotere label was updated to include mention of permanent hair loss as a potential side effect.

Alopecia often accompanies chemotherapy. However, plaintiffs in Taxotere lawsuits charge that it is far more likely to cause permanent hair loss compared to other, equally effective chemotherapy agents.

Among other things, they note that doctors and patients were informed of the potential for permanent hair loss in 2005, while the Canadian label underwent a similar modification in 2012.  By contrast, the U.S. prescribing information only included a vaguely worded and insufficient statement that “hair generally grows back.”

Taxotere and Permanent Hair Loss

According to Taxotere lawsuits, permanent alopecia associated with its use results in baldness, as well as the loss of eyelashes, eyebrows and pubic hair. Plaintiffs claim that Sanofi-Aventis has long been aware of this potential side effect, and cite several studies that have suggested a link between Taxotere and persistent hair loss, including:

  • The GEICAM 9805 clinical trial – funded by Sanofi – suggested that 9.2% of Taxotere patients suffered hair loss that lasted 10 years or longer.
  • In 2006, a Denver-based oncologist reported that 6.3% of his Taxotere patients had experienced permanent alopecia.
  • A 2012 study published in the Annals of Oncology followed 20 Taxotere patients, 19 of whom had permanent hair loss, including the loss of their eyebrows and eyelashes. The authors of the paper cautioned that “physicians and patients should be aware of this new distressing side-effect.”

Source